title: Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
abstract: Organic anion-transporting polypeptides (OATPs) are multispecific transporters mediating the uptake of endogenous compounds and xenobiotics in tissues that are important for drug absorption and elimination, including the intestine and liver. Silymarin is a popular herbal supplement often used by patients with chronic liver disease; higher oral doses than those customarily used (140 mg three times/day) are being evaluated clinically. The present study examined the effect of silymarin flavonolignans on OATP1B1-, OATP1B3-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes. In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated. OATP1B1-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC₅₀ values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC₅₀ values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC₅₀ values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC₅₀ values of 9.0, 36.4, and 3.6 µM, respectively). Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited OATP-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes. Calculation of the maximal unbound portal vein concentrations/IC₅₀ values indicated a low risk for silymarin-drug interactions in hepatic uptake with a customary silymarin dose. The extent of silymarin-drug interactions depends on OATP isoform specificity and concentrations of flavonolignans at the site of drug transport. Higher than customary doses of silymarin, or formulations with improved bioavailability, may increase the risk of flavonolignan interactions with OATP substrates in patients.
authors: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
authors: Kathleen
authors: K
authors: Köck
authors: Ying
authors: Y
authors: Xie
authors: Roy L
authors: RL
authors: Hawke
authors: Nicholas H
authors: NH
authors: Oberlies
authors: Kim L R
authors: KL
authors: Brouwer
mesh_terms: D005464:Fluorobenzenes / Q000378:metabolism; D057809:HEK293 Cells; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D027361:Organic Anion Transporters / Q000187:drug effects* / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D000068718:Rosuvastatin Calcium; D012838:Silymarin / Q000378:metabolism / Q000494:pharmacology*; D013449:Sulfonamides / Q000378:metabolism
chemical_list: D005464:Fluorobenzenes; D027361:Organic Anion Transporters; D011743:Pyrimidines; D012838:Silymarin; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium
references: JAMA. 2012 Jul 18;308(3):274-82
references: 22797645
references: J Pharmacol Exp Ther. 2003 Aug;306(2):703-8
references: 12724351
references: AAPS PharmSciTech. 2010 Jun;11(2):672-8
references: 20405254
references: Drug Metab Dispos. 2006 Jul;34(7):1109-15
references: 16611857
references: Drug Metab Dispos. 2009 May;37(5):1129-37
references: 19237515
references: J Pharmacol Exp Ther. 2010 Mar;332(3):1081-7
references: 19934397
references: J Pharmacol Exp Ther. 2011 Nov;339(2):624-32
references: 21846839
references: Drug Metab Dispos. 2006 Apr;34(4):577-82
references: 16415120
references: Clin Pharmacol Ther. 2006 Dec;80(6):607-20
references: 17178262
references: Drug Metab Dispos. 2005 Mar;33(3):434-9
references: 15608127
references: J Ethnopharmacol. 2009 Jan 21;121(2):185-93
references: 19041708
references: Pharmacol Rev. 1998 Sep;50(3):387-412
references: 9755288
references: Br J Clin Pharmacol. 2011 May;71(5):718-26
references: 21204914
references: Hepatology. 1989 Feb;9(2):297-301
references: 2643548
references: Curr Pharm Biotechnol. 2012 Aug;13(10):1964-70
references: 22352731
references: J Pharmacol Exp Ther. 2004 Feb;308(2):438-45
references: 14610227
references: Planta Med. 2007 Nov;73(14):1495-501
references: 17948171
references: Drug Metab Dispos. 2012 Oct;40(10):2009-20
references: 22822035
references: Drug Metab Dispos. 2008 Jan;36(1):65-72
references: 17913795
references: Drug Metab Dispos. 2008 Oct;36(10):2014-23
references: 18617601
references: J Pharm Biomed Anal. 2007 Nov 30;45(4):635-41
references: 17692492
references: Expert Rev Clin Pharmacol. 2011 Nov;4(6):729-42
references: 22111859
references: Nat Rev Drug Discov. 2010 Mar;9(3):215-36
references: 20190787
references: Drug Metab Dispos. 2011 Nov;39(11):2093-102
references: 21849517
references: J Clin Pharmacol. 2010 Apr;50(4):434-49
references: 19841158
references: Am J Physiol Gastrointest Liver Physiol. 2000 Jan;278(1):G156-64
references: 10644574
references: J Biol Chem. 2000 Jul 28;275(30):23161-8
references: 10779507
references: Drug Metab Dispos. 2005 Apr;33(4):518-23
references: 15640378
references: Cancer Biol Ther. 2005 Aug;4(8):815-8
references: 16210916
references: J Biomed Nanotechnol. 2012 Oct;8(5):760-9
references: 22888746
references: Prostate. 2010 Jun 1;70(8):848-55
references: 20127732
references: J Clin Endocrinol Metab. 2002 Apr;87(4):1856-63
references: 11932330
references: Pflugers Arch. 2004 Feb;447(5):653-65
references: 14579113
references: J Clin Pharmacol. 2011 May;51(5):751-60
references: 20974993
references: Pharm Res. 2008 Aug;25(8):1807-14
references: 18236139
references: J Biol Chem. 1999 Dec 24;274(52):37161-8
references: 10601278
references: Hepatology. 2008 Feb;47(2):605-12
references: 18157835
references: Drug Metab Dispos. 2011 May;39(5):920-6
references: 21278283
references: Toxicol Sci. 2006 May;91(1):140-9
references: 16495352
references: Arch Pharm Res. 2007 Jan;30(1):82-9
references: 17328246
references: Pharmacogenet Genomics. 2009 Feb;19(2):129-38
references: 19151602
references: Aliment Pharmacol Ther. 2011 Jan;33(1):127-37
references: 21083592
references: J Med Chem. 2012 May 24;55(10):4740-63
references: 22541068
references: Biochem Pharmacol. 2010 Dec 1;80(11):1746-53
references: 20797388
references: J Clin Pharmacol. 2008 Nov;48(11):1323-38
references: 18784280
references: Mol Pharmacol. 2006 Nov;70(5):1735-41
references: 16908597
references: J Pharmacol Exp Ther. 2004 Oct;311(1):139-46
references: 15159445